Cargando…
Sotrovimab: First Approval
Sotrovimab (Xevudy(®)) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline for the treatment of coronavirus disease 2019 (COVID-19). Sotrovimab received its f...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919156/ https://www.ncbi.nlm.nih.gov/pubmed/35286623 http://dx.doi.org/10.1007/s40265-022-01690-7 |